Litigation Update: Case Management Statement in Amgen v. Sandoz (filgrastim, pegfilgrastim)

Amgen v. Sandoz (filgrastim)  •  Amgen v. Sandoz (pegfilgrastim)  •  Approved Biosimilar Products

The parties in Amgen v. Sandoz (N.D. Cal.) (filgrastim and pegfilgrastim) have submitted a joint case management statement regarding the two pending cases between the parties: Case No. 3:14-cv-04741-RS (accused product: Zarxio® (filgrsatim-sndz), which Sandoz launched in September, 2015) and Case No. 3:16-cv-02581-RS (accused product: pegfilgrastim (biosimilar to Amgen’s Neulasta®).

The parties propose a 7- to 9-day trial beginning the week of December 11, 2017.

Stay tuned to the Big Molecule Watch for further updates.

Download PDF

Comments are closed.